MTOR and hematologic disorder: The mTOR inhibitors everolimus (Afinitor®) and temsirolimus (Torisel®) are currently under clinical investigation for the treatment of NHL and HL, and ridaforolimus (formerly deforolimus) is being evaluated in patients with hematological malignancies including lymphoma.